SPONSORED:

House passes sweeping Pelosi bill to lower drug prices

The House on Thursday passed a sweeping bill aimed at lowering prescription drug prices, a step toward a long-held Democratic goal that was met with sharp Republican resistance.

The bill passed on a largely party-line vote of 230-192. The measure, which would allow the government to negotiate lower prices for prescription drugs, is one of House Democrats’ top priorities and is expected to be touted by vulnerable Democrats up for reelection next year.

The party is also looking to show that it is focused on kitchen table issues like lowering drug costs even as lawmakers prepare for an impeachment vote against President TrumpDonald John TrumpTrump rages against '60 Minutes' for interview with Krebs Cornyn spox: Neera Tanden has 'no chance' of being confirmed as Biden's OMB pick Pa. lawmaker was informed of positive coronavirus test while meeting with Trump: report MORE.

ADVERTISEMENT

“What I hear most often is not impeachment, it's not what's on the front page of The Washington Post, it's ‘What are you going to do about the cost of our prescription drugs?’ ” said Rep. Kim SchrierKimberly (Kim) Merle SchrierRep. Kim Schrier defends Washington House seat from GOP challenger House approves .2T COVID-19 relief bill as White House talks stall Pelosi: House will stay in session until agreement is reached on coronavirus relief MORE (D-Wash.), one of several freshmen facing competitive reelection races who showcased the bill on the Capitol steps Thursday. “And this bill is an answer to my constituents.”

Two Republicans voted in favor of the bill: Reps. Brian FitzpatrickBrian K. FitzpatrickDemocrats were united on top issues this Congress — but will it hold? Divided citizenry and government — a call to action for common ground OVERNIGHT ENERGY: Down ballot races carry environmental implications | US officially exits Paris climate accord  MORE (Pa.) and Jaime Herrera BeutlerJaime Lynn Herrera BeutlerHouse Hispanic Republicans welcome four new members GOP Rep. Jaime Herrera Beutler wins reelection Mild weather could boost voter turnout on Election Day MORE (Wash.), both moderates who face competitive reelection races next year. No Democrats voted against the bill.

The measure drew support from progressives following months of negotiations that cleared the way for it to pass this week. The bill is almost certain to die in the GOP-led Senate, though, given that Senate Majority Leader Mitch McConnellAddison (Mitch) Mitchell McConnellFive things to know about Georgia's Senate runoffs Obama chief economist says Democrats should accept smaller coronavirus relief package if necessary Memo to Biden: Go big — use the moment to not only rebuild but to rebuild differently MORE (R-Ky.) has called it “socialist” and vowed to block it. Republicans warn the measure would hinder the development of new treatments and impose “price controls.”

It is possible that smaller measures to lower drug prices could become law, given a bipartisan push to do something on the topic, but a path forward remains unclear amid division and multiple competing proposals.

Pelosi had tried for months to win Trump’s support for the bill, given that he broke from Republican orthodoxy and supported government negotiation on drug prices during his 2016 campaign.

After months of talks between Pelosi’s staff and the White House, though, the administration came out against the measure, leading Democrats to say Trump is breaking his promise to support negotiation for lower prices.

ADVERTISEMENT

“It’s exactly what President Trump promised on the campaign trail,” said Rep. Andy LevinAndrew (Andy) LevinThe Hill's Morning Report - Presented by the UAE Embassy in Washington, DC - Trump OKs transition; Biden taps Treasury, State experience Five House Democrats who could join Biden Cabinet What's behind the divisions over Biden's secretary of Labor? MORE (D-Mich.).

Trump is instead supporting a more modest bipartisan bill in the Senate to lower drug prices, legislation that does not include a provision to negotiate prices.

The House bill, known as the Elijah E. Cummings Lower Drug Costs Now Act, is named for the late Democratic lawmaker who was a champion of lowering drug prices.

The legislation would allow the secretary of Health and Human Services to negotiate lower prices for a minimum of 50 drugs per year, up to a maximum of 250 drugs. The prices for those drugs would also be capped at 120 percent of the prices in certain other wealthy countries. The government would then negotiate to bring prices down even further below that cap.

The lower prices would apply to people on private insurance in addition to those on Medicare.

If a drug company refused to negotiate, the company would be hit with a tax up to 95 percent of the revenue for the drug.

That steep penalty has led Republicans to argue the bill is not really “negotiation” as Democrats claim, but is effectively just mandating the price that drug companies must sell their products at.

The White House said the bill would impose “price controls” in its message threatening to veto the measure.

Progressive House Democrats had resisted the bill from the other direction, arguing that the measure did not go far enough. Reps. Pramila JayapalPramila JayapalInequality of student loan debt underscores possible Biden policy shift Biden Cabinet picks largely unify Democrats — so far Democrats brush off calls for Biden to play hardball on Cabinet picks MORE (D-Wash.) and Mark PocanMark William PocanCapitol's COVID-19 spike could be bad Thanksgiving preview Katherine Clark secures No. 4 leadership spot for House Democrats Democrats to determine leaders after disappointing election MORE (D-Wis.), along with Rep. Lloyd DoggettLloyd Alton DoggettCongress must repeal tax breaks for the wealthy passed in CARES Act Ocasio-Cortez, progressives call on Senate not to confirm lobbyists or executives to future administration posts Trump order on drug prices faces long road to finish line MORE (D-Texas), spent months pushing Pelosi to make the bill tougher.

In recent days they threatened to try to block a vote on the bill unless changes were made, but struck a deal with Pelosi after a meeting in the Speaker’s office Tuesday, clearing the way for the bill to pass with minimal drama. One of the changes increased the minimum number of drugs to be negotiated from 35 to 50.

The Congressional Budget Office (CBO) found the bill would lower prices by about 50 percent for drugs subject to negotiation and save $456 billion over 10 years. The bill then invests those savings in expanding Medicare benefits to include hearing, dental and vision care.

On the other hand, the CBO also found the bill would result in eight fewer drugs being developed over a decade, out of about 300 usually introduced in that time period. 

ADVERTISEMENT

House Republicans put forward a competing proposal that also received a vote Thursday. Their bill is much smaller in scale. Republicans touted it as leading to lower prices without imposing “price controls” or threatening the development of new drugs. 

House Minority Leader Kevin McCarthyKevin Owen McCarthyDemocrats were united on top issues this Congress — but will it hold? Top Republicans praise Trump's Flynn pardon Richmond says GOP 'reluctant to stand up and tell the emperor he wears no clothes' MORE (R-Calif.) called the Democratic bill a move to “appease the progressive base and have a partisan bill that denies us more cures,” while calling the GOP alternative a “practical solution” that would still allow new cures to come to market.

Democrats say polling shows the public is behind their bill. The progressive group Data for Progress on Thursday released polling testing different messages about the bill and finding strong support. Opposition never rose above 40 percent even when voters were presented with only negative messages about the bill. 

Pelosi said on the House floor on Thursday that she did not know why the White House stopped working with her on the drug pricing bill.

“We were working with the interests of the White House, the administration, on all of this,” she said. “I don't where it happened, but somewhere along the way, negotiation and the rest fell by the by. And what that could be attributed to, I don't know what.”

Updated: 2:30 p.m.